Literature DB >> 23132491

Toll-like receptor 2-dependent activity of native major outer membrane protein proteosomes of Chlamydia trachomatis.

Paola Massari1, Deana N Toussi, Delia F Tifrea, Luis M de la Maza.   

Abstract

Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen and the etiologic agent of blinding trachoma. Intracellular signaling pathways leading to host cell inflammation and innate immunity to Chlamydia include those mediated by Toll-like receptors (TLRs) and nucleotide binding oligomerization domain 1 (Nod1) protein. In epithelial cells, TLR-dependent signaling contributes to local immune responses via induction of inflammatory mediators. There is evidence that TLR3, TLR4, and, particularly, TLR2 are critical for Chlamydia-mediated host cell activation and pathology. Despite the importance of TLR2, major chlamydial TLR2 antigens have not been identified so far. Numerous bacterial porins are known TLR2 agonists, i.e., porins from Neisseriae, Shigella, Salmonella, Haemophilus influenzae, and Fusobacterium nucleatum, which share structural and functional similarities with the chlamydial major outer membrane protein (MOMP), a strong antigen candidate for a potential vaccine against C. trachomatis. We describe the ability of purified, detergent-free MOMP to signal via TLR2 in vitro in TLR-overexpressing cells and TLR2-competent human reproductive tract epithelial cell lines. Using MOMP formed in pure protein micelles (proteosomes), we show the induction of TLR2-dependent interleukin-8 (IL-8) and IL-6 secretion in vitro, the involvement of TLR1 as a TLR2 coreceptor, and the activation of both NF-κB and mitogen-activated protein (MAP) kinase intracellular pathways. Interestingly, MOMP proteosomes induce cytokine secretion in endocervical epithelial cells (End/E6E7) but not in urethral epithelial cells (THUECs). A detailed understanding of the TLR2-dependent molecular mechanisms that characterize the effect of MOMP proteosomes on host cells may provide new insights for its successful development as an immunotherapeutic target against Chlamydia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132491      PMCID: PMC3536141          DOI: 10.1128/IAI.01062-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma.

Authors:  L A Jackson; L A Campbell; R A Schmidt; C Kuo; A L Cappuccio; M J Lee; J T Grayston
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

Review 2.  Toll-like receptors: critical proteins linking innate and acquired immunity.

Authors:  S Akira; K Takeda; T Kaisho
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

3.  Porin of Shigella dysenteriae activates mouse peritoneal macrophage through Toll-like receptors 2 and 6 to induce polarized type I response.

Authors:  Amlan Biswas; Pallavi Banerjee; Gayatri Mukherjee; Tapas Biswas
Journal:  Mol Immunol       Date:  2006-06-05       Impact factor: 4.407

4.  Improved purification of native meningococcal porin PorB and studies on its structure/function.

Authors:  Paola Massari; Carol A King; Heather MacLeod; Lee M Wetzler
Journal:  Protein Expr Purif       Date:  2005-05-31       Impact factor: 1.650

5.  Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling.

Authors:  Paola Massari; Alberto Visintin; Jay Gunawardana; Kristen A Halmen; Carol A King; Douglas T Golenbock; Lee M Wetzler
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

6.  The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.

Authors:  F Hayashi; K D Smith; A Ozinsky; T R Hawn; E C Yi; D R Goodlett; J K Eng; S Akira; D M Underhill; A Aderem
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

7.  Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions. Evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen.

Authors:  Catherine M O'Connell; Irina A Ionova; Alison J Quayle; Alberto Visintin; Robin R Ingalls
Journal:  J Biol Chem       Date:  2005-11-17       Impact factor: 5.157

8.  Stimulation of the cytosolic receptor for peptidoglycan, Nod1, by infection with Chlamydia trachomatis or Chlamydia muridarum.

Authors:  Lynn Welter-Stahl; David M Ojcius; Jérôme Viala; Stéphane Girardin; Wei Liu; Christiane Delarbre; Dana Philpott; Kathleen A Kelly; Toni Darville
Journal:  Cell Microbiol       Date:  2006-06       Impact factor: 3.715

9.  Susceptibility of prostate epithelial cells to Chlamydia muridarum infection and their role in innate immunity by recruitment of intracellular Toll-like receptors 4 and 2 and MyD88 to the inclusion.

Authors:  Juan Pablo Mackern-Oberti; Mariana Maccioni; Cecilia Cuffini; Gerardo Gatti; Virginia E Rivero
Journal:  Infect Immun       Date:  2006-09-05       Impact factor: 3.441

10.  Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses.

Authors:  D H Wyllie; E Kiss-Toth; A Visintin; S C Smith; S Boussouf; D M Segal; G W Duff; S K Dower
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

View more
  19 in total

1.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

2.  Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis.

Authors:  Lucian Visan; Violette Sanchez; Margaux Kania; Aymeric de Montfort; Luis M de la Maza; Salvador Fernando Ausar
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

3.  Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells.

Authors:  Saurabh Dixit; Rajnish Sahu; Richa Verma; Skyla Duncan; Guillermo H Giambartolomei; Shree R Singh; Vida A Dennis
Journal:  Biomaterials       Date:  2017-12-26       Impact factor: 12.479

Review 4.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

Review 5.  Sensing the enemy, containing the threat: cell-autonomous immunity to Chlamydia trachomatis.

Authors:  Ryan Finethy; Jörn Coers
Journal:  FEMS Microbiol Rev       Date:  2016-11-01       Impact factor: 16.408

6.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

7.  SslE (YghJ), a Cell-Associated and Secreted Lipoprotein of Neonatal Septicemic Escherichia coli, Induces Toll-Like Receptor 2-Dependent Macrophage Activation and Proinflammation through NF-κB and MAP Kinase Signaling.

Authors:  Rima Tapader; Dipro Bose; Pujarini Dutta; Santasabuj Das; Amit Pal
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

8.  Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.

Authors:  Saurabh Dixit; Shree R Singh; Abebayehu N Yilma; Ronald D Agee; Murtada Taha; Vida A Dennis
Journal:  Nanomedicine       Date:  2014-03-04       Impact factor: 5.307

9.  Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.

Authors:  Delia F Tifrea; Sukumar Pal; Christel le Bon; Melanie J Cocco; Manuela Zoonens; Luis M de la Maza
Journal:  Vaccine       Date:  2020-04-30       Impact factor: 3.641

Review 10.  T cell responses to Chlamydia.

Authors:  Jennifer D Helble; Michael N Starnbach
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.